RNF165

Across TCGA pan-cancer cohorts, RNF165 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RNF165 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in thyroid carcinoma (THCA), where higher RNF165 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RNF165 expression acts as an unfavorable survival marker.

THCA, SKCM, and PRAD are the cancer types where RNF165 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THCA	DFS	Median	All	0.100	0.841	<.001	18	view →
SKCM	DFS	Median	All	0.276	0.763	<.001	10	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUAD	OS	Median	All	0.383	0.687	.019	6	view →
ACC	DFS	Median	All	0.180	0.659	.001	3	view →
ESCA	OS	Median	II,III,IV	0.362	0.706	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RNF165–THCA (DFS)

Open the THCA breakdown →